Variant report
Variant | nsv518449 |
---|---|
Chromosome Location | chr2:125135589-125142722 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs552135397 | chr2:125139605-125139606 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs147720356 | chr2:125139606-125139607 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs537773653 | chr2:125139648-125139649 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs554398842 | chr2:125139675-125139676 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs185050141 | chr2:125139678-125139679 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs533731694 | chr2:125139750-125139751 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs554000901 | chr2:125139818-125139819 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
8 | rs114720262 | chr2:125139826-125139827 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
9 | rs189565249 | chr2:125139827-125139828 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
10 | rs142498752 | chr2:125139950-125139951 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
11 | rs2584358 | chr2:125140020-125140021 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
12 | rs145890799 | chr2:125140053-125140054 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
13 | rs527937366 | chr2:125140055-125140056 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
14 | rs368219554 | chr2:125140078-125140079 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
15 | rs533368061 | chr2:125140096-125140097 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
16 | rs532249945 | chr2:125140154-125140155 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
17 | rs551960652 | chr2:125140216-125140217 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
18 | rs550298659 | chr2:125140254-125140255 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
19 | rs568518657 | chr2:125140288-125140289 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
20 | rs1425743 | chr2:125140295-125140296 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
21 | rs182099558 | chr2:125140330-125140331 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
22 | rs201581457 | chr2:125140419-125140420 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs186042924 | chr2:125140430-125140431 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs151162649 | chr2:125140437-125140438 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs553944999 | chr2:125140468-125140469 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs554980250 | chr2:125140477-125140478 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs140123564 | chr2:125140488-125140489 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs539925886 | chr2:125140513-125140514 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs556654589 | chr2:125140522-125140523 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs191106569 | chr2:125140529-125140530 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs576545853 | chr2:125140541-125140542 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs542240083 | chr2:125140627-125140628 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
33 | rs150294250 | chr2:125140632-125140633 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs181763695 | chr2:125140633-125140634 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs535466591 | chr2:125140704-125140705 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs185339772 | chr2:125140733-125140734 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs564725052 | chr2:125140748-125140749 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs533320475 | chr2:125140787-125140788 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs375387654 | chr2:125140813-125140814 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs545896076 | chr2:125140862-125140863 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs369034097 | chr2:125140872-125140873 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs138111815 | chr2:125140887-125140888 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
43 | rs114997285 | chr2:125140888-125140889 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs113786329 | chr2:125140927-125140928 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs191179482 | chr2:125140946-125140947 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs552050753 | chr2:125140996-125140997 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
47 | rs200492979 | chr2:125140997-125140998 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs547328255 | chr2:125141008-125141009 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs552638676 | chr2:125141011-125141012 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs182553507 | chr2:125141029-125141030 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Medulloblastoma | 21979893 | CNVD |
Breast cancer | 17603634 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Ependymoma | 16718352 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Intellectual disability | 22102821 | CNVD |
Cancer | 20164919 | CNVD |
Autism | 22495311 | CNVD |
Autism | 18522746 | CNVD |
Neurodevelopmental disorder | 22521361 | CNVD |
Melanoma | 18172304 | CNVD |
Cancer | 16751803 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Acute lymphoblastic leukemia | 21980252 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Seminomas | 18059402 | CNVD |
Testicular germ cell tumor | 18059402 | CNVD |
Myxofibrosarcoma | 16751306 | CNVD |
Breast cancer | 16272173 | CNVD |
Lung cancer | 18438408 | CNVD |
Mowat-Wilson syndrome | 21572526 | CNVD |
Disorders of sex development | 21048976 | CNVD |
epilepsy | 18472482 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Cancer | 21637783 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Liposarcoma | 21253554 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Embryonal rhabdomyosarcoma | 16790082 | CNVD |
Autism | 16446308 | CNVD |
Autism | 19401682 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Splenic marginal zone lymphoma | 21957467 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Colorectal cancer | 16272173 | CNVD |
myoclonus epilepsy | 18472482 | CNVD |
Benign familial neonatal-infantile seizures | 18472482 | CNVD |
Diffuse large b-cell lymphoma | 18287131 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Mental retardation | 17621639 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
Prostate cancer | 16573809 | CNVD |
Prostate cancer | 18632612 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Glioblastoma multiforme | 22286061 | CNVD |
Medulloblastoma | 16968546 | CNVD |
Neurocytoma | 17123091 | CNVD |
Developmental delay | 21147756 | CNVD |
Bladder cancer | 21909424 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
Breast cancer | 22522925 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr2:125139600-125139800 | Enhancers | H9 Cell Line | embryonic stem cell |
2 | chr2:125139800-125140400 | Weak transcription | H9 Cell Line | embryonic stem cell |
3 | chr2:125140400-125141000 | Enhancers | H9 Cell Line | embryonic stem cell |
4 | chr2:125140600-125141200 | Enhancers | HUES64 Cell Line | embryonic stem cell |
5 | chr2:125141000-125142200 | Weak transcription | H9 Cell Line | embryonic stem cell |
6 | chr2:125142400-125142600 | Enhancers | H9 Cell Line | embryonic stem cell |